CureVac

✨🎉We could not possibly close out the year without a festive gathering as a team to celebrate all the many successes we’ve achieved together.   Our 2024 Holiday Party was one to remember – and while the atmosphere and décor were certainly a perk of the evening, having fun and spending time with our fantastic team was undoubtedly the main highlight.   A huge thanks to our #RNAPeople for all their hard work and commitment to transforming the future of medicine.   Check out some pictures from the party below!   #Teamwork #mRNA #biotech

We’re looking forward to heading out once again to San Francisco in January for the 43rd Annual J. P. Morgan Healthcare Conference!   Members of our leadership team will there – if you’re interested in connecting in person, please reach out to the Precision AQ team via this link to schedule a 1X1 meeting with us while there: https://lnkd.in/gEsWCVhj   #JPM2025 #HealthcareInnovation #mRNA #JPM #Biotech

The Piper Sandler 36th Annual Healthcare Conference marks our final stop in NYC for 2024! Our CEO Alexander Zehnder, MD, MBA and CBO Thaminda Ramanayake are speaking with the investor community about the exciting, and recently-announced, expansion of our pipeline as well as the enormous potential of mRNA to help address some of the greatest medical needs of today.   #mRNA #HealthcareInnovation #Oncology #InfectiousDisease  

We’re excited to have a presence at the 7th Annual Evercore HealthCONx Conference in Miami today. It is wonderful to have an opportunity to connect with innovative industry peers and investors who are collectively driving forward and making possible robust transformation in healthcare. We greatly enjoy engaging in conversations around how mRNA is and will continue to play a major role in reshaping healthcare and medicine as we know it. #HealthCONx2024 #mRNA #healthcare

The team is on the road again – this time in London for the prestigious Jefferies London Healthcare Conference 2024. The energy at this event is incredible, as always. We have very much enjoyed discussing with the investment community how we’re innovating in the mRNA space and what’s next on the horizon. At CureVac, we believe the opportunities that mRNA can open in human health are vast, and we’re working swiftly to unlock its potential across different applications.   #JefferiesHealthcare #mRNA #biotech #HealthcareInnovation

Our Dominik Vahrenhorst, Associate Director of Bioinformatics, will be leading a roundtable discussion tomorrow on the future of drug development with AI at the AI in Drug Discovery Xchange Europe 2024 conference. The discussion will span a variety of important topics including how AI can improve the design of drugs, existing challenges in drug design, how to address those challenges and more! You can find additional information here: https://lnkd.in/ewwBdbmS #hubXchange #AiinDrugDiscovery #innovation #biotech #mRNA #DrugDiscovery

It was great to have so much of our team in Boston this past week at the International mRNA Health Conference. At the close of the conference, we caught up with our CSO Dr. Myriam Mendila who reflected on the three things that made it particularly memorable for her, including CureVac’s many contributions while there.    Hear from Myriam as she describes the very exciting science we’re working on across both oncology and infectious disease.   It was a fantastic and informative conference, and we’re already looking forward to next year’s!   #mRNA2024 #mRNAHealthConference #CancerVaccine #mRNA

On the heels of our quarterly earnings announcement on Tuesday, where we revealed two new programs, we have spent the last 48 hours connecting with investors on our exciting plans for the future. Our first stop was Boston, where we were delighted to participate in the inaugural Guggenheim Securities Healthcare Innovation Conference on Wednesday. Today we are in New York, participating in a road show to underscore our unique value proposition as we work to innovate in the ever-evolving, ever-exciting mRNA space.   #Biotech #mRNA #HealthcareInnovation

CureVac has long been proud to be a founding member of the International mRNA Health Conference. While at this year’s conference in Boston this week – which marks its 12th gathering – our CEO Alexander Zehnder, MD, MBA spoke a bit to the general energy at the conference as well as the latest developments at CureVac and why it excites him for the future ahead.    Check it out!   Also, you can learn more about our newest programs in our recent earnings press release here: https://lnkd.in/gsep92wj   #mRNA2024 #mRNAHealthConference #CancerVaccine #mRNA

Today, we announced the financial results for the third quarter and first nine months of 2024 as well as shared business updates and unveiled plans going forward. We closed the third quarter 2024 with a strong cash balance of €550.9 million, providing us with a solid financial runway into 2028. Beyond spotlighting some of the latest data shared at recent medical conferences from our ongoing Phase 1 CVGBM glioblastoma study, we were pleased to announce this morning plans around additional indications we are pursuing. On the infectious disease front, we have just initiated a new preclinical prophylactic vaccine program for urinary tract infections. Did you know that UTIs are among the most common bacterial infections and result in millions of doctor appointments a year in the U.S. alone? Additionally, in oncology, we have expanded our work to include a program for squamous non-small cell lung cancer, which is expected to enter the clinic in the second half of 2025. For more information, please find our press release here: https://lnkd.in/gsep92wj #InfectiousDisease #mRNA #Oncology #Innovation